[go: up one dir, main page]

PT1090033E - Particulas de proteinas de envelope do hcv: utilizacao para vacinacao - Google Patents

Particulas de proteinas de envelope do hcv: utilizacao para vacinacao

Info

Publication number
PT1090033E
PT1090033E PT99929306T PT99929306T PT1090033E PT 1090033 E PT1090033 E PT 1090033E PT 99929306 T PT99929306 T PT 99929306T PT 99929306 T PT99929306 T PT 99929306T PT 1090033 E PT1090033 E PT 1090033E
Authority
PT
Portugal
Prior art keywords
hcv
vaccination
envelope protein
protein particles
hcv envelope
Prior art date
Application number
PT99929306T
Other languages
English (en)
Inventor
Geert Maertens
Bosman Alfons
Depla Erik
Wijnendaele Van Frans
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1090033(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of PT1090033E publication Critical patent/PT1090033E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT99929306T 1998-06-24 1999-06-23 Particulas de proteinas de envelope do hcv: utilizacao para vacinacao PT1090033E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870142 1998-06-24
EP99870033 1999-02-22
PCT/EP1999/004342 WO1999067285A1 (en) 1998-06-24 1999-06-23 Particles of hcv envelope proteins: use for vaccination

Publications (1)

Publication Number Publication Date
PT1090033E true PT1090033E (pt) 2005-05-31

Family

ID=26152268

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99929306T PT1090033E (pt) 1998-06-24 1999-06-23 Particulas de proteinas de envelope do hcv: utilizacao para vacinacao

Country Status (20)

Country Link
US (3) US6635257B1 (pt)
EP (2) EP1090033B2 (pt)
JP (1) JP2002518037A (pt)
KR (1) KR100559096B1 (pt)
CN (1) CN1313864A (pt)
AT (1) ATE286067T1 (pt)
AU (1) AU765940B2 (pt)
BR (1) BR9911397A (pt)
CA (1) CA2330526A1 (pt)
DE (1) DE69922958T3 (pt)
DK (1) DK1090033T4 (pt)
ES (1) ES2237115T5 (pt)
HU (1) HU227275B1 (pt)
IL (2) IL140217A0 (pt)
NZ (2) NZ508797A (pt)
PL (1) PL201679B1 (pt)
PT (1) PT1090033E (pt)
RU (1) RU2247729C2 (pt)
TR (1) TR200003843T2 (pt)
WO (1) WO1999067285A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
DE69922958T3 (de) * 1998-06-24 2008-06-26 Innogenetics N.V. Hcv hüllproteine partikel : verwendung für therapeutische impfung
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
PT1221968E (pt) * 1999-10-13 2010-04-16 Novartis Vaccines & Diagnostic Processo de obtenção de respostas imunes celulares de proteínas
DE60100814T2 (de) 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
WO2002019963A2 (en) * 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Synthetic erythropoiesis stimulating proteins
EP1326625A4 (en) * 2000-09-13 2005-05-04 Hawaii Biotech Inc IMMUNOGENIC COMPOSITION OF HEPATITIS C AND METHODS OF USING THE SAME
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
CA2443781A1 (en) 2001-04-24 2002-10-31 Innogenetics N.V. Core-glycosylated hcv envelope proteins
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
CA2468690A1 (en) * 2001-12-18 2003-06-26 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
FR2839722A1 (fr) 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
JP2004085528A (ja) * 2002-07-05 2004-03-18 Kansai Tlo Kk 拡散定数変化による蛋白質の会合検出方法及び装置
EP1852441B1 (en) * 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
CA2499580A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
EP1481985A1 (en) * 2003-05-28 2004-12-01 Innogenetics N.V. Modified hepatitis C virus (HCV) NS3 for medical treatment
EP1561470A1 (en) * 2003-06-20 2005-08-10 Innogenetics N.V. HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent
BRPI0415202A (pt) * 2003-10-10 2006-12-05 Powderject Vaccines Inc método de eliciar uma resposta de célula t contra um epìtopo de célula t em um indivìduo mamìfero hospedeiro, ensaio para testar a eficácia de um método de eliciar uma resposta de célula t, e, kit para realizar os mesmos
WO2006070028A1 (es) * 2004-12-23 2006-07-06 Berthet Francois Xavier Composiciones y procedimientos para detectar infección patógena
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
WO2006033012A2 (en) * 2004-09-24 2006-03-30 Pfizer Limited Method of screening for modulators of hepatitis c virus infection
DE102004057111A1 (de) 2004-11-26 2006-06-01 Niles-Simmons Industrieanlagen Gmbh Verfahren zum Zwischenbearbeiten von Wellen
AU2006208068B2 (en) 2005-01-27 2011-08-04 The Burnham Institute EphB receptor-binding peptides
WO2007041432A2 (en) * 2005-09-30 2007-04-12 Novartis Vaccines And Diagnostics, Inc. Cross-neutralization of hcv with recombinant proteins
US20090311248A1 (en) * 2006-03-22 2009-12-17 Erik Depla Hepatitis C Virus Neutralizing Antibodies
RU2329303C2 (ru) * 2006-08-02 2008-07-20 Государственное учреждение Научно-исследовательский институт вирусологии им. Д.И. Ивановского Российской академии медицинских наук Моноклональное антитело, иммунореактивное с белком нуклеокапсида (кор) вируса гепатита с-4g5, способ диагностики вгс-инфекции и комбинация моноклональных антител для его осуществления
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
US20110091495A1 (en) * 2008-04-22 2011-04-21 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
US20110217330A1 (en) * 2008-11-05 2011-09-08 Bruno Rene Andre Novel method
BR112013032675A2 (pt) * 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
JP6567824B2 (ja) * 2011-10-12 2019-08-28 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
RU2510998C2 (ru) * 2012-08-01 2014-04-10 Николай Николаевич Грановский ВАКЦИНА НА ОСНОВЕ ВИРУСОПОДОБНЫХ ЧАСТИЦ, СОДЕРЖАЩИХ ВСЕ СТРУКТУРНЫЕ АНТИГЕНЫ ВИРУСА ГЕПАТИТА С, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ В ДРОЖЖАХ Hansenula polymorpha
EP2968527A4 (en) 2013-03-12 2016-08-17 Univ Pennsylvania IMPROVED VACCINES AGAINST HUMAN PAPILLOMA VIRUS AND METHOD FOR USE THEREOF
US11324818B2 (en) 2016-09-21 2022-05-10 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
JP6795468B2 (ja) * 2017-07-14 2020-12-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法
JP7075130B2 (ja) * 2019-10-25 2022-05-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒトパピローマウイルスのワクチンおよびその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395395A (en) * 1979-05-21 1983-07-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of non-A, non-B hepatitis associated antigen
RU2175657C2 (ru) * 1990-11-08 2001-11-10 Чирон Корпорейшн Асиалогликопротеин вируса гепатита c (нсv), иммуногенная композиция, способ индукции иммунного ответа, способ иммуноанализа
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
DK0992580T3 (da) * 1993-11-04 2005-07-11 Innogenetics Nv Epitoper på human T-celler, som er immundominante for hepatitis C-virus
EP1845108A3 (en) * 1994-07-29 2007-10-24 Innogenetics N.V. Monoclonal antibodies to purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
EP1076092A3 (en) * 1994-10-21 2001-03-28 Innogenetics N.V. Sequences of hepatitis C virus type10 and their use as prophylactic, therapeutic and diagnostic agents
AU738585B2 (en) 1996-11-08 2001-09-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthesis and purification of hepatitis C virus-like particles
ES2310701T3 (es) * 1998-04-17 2009-01-16 Innogenetics N.V. Metodos para mejorar la conformacion de proteinas por medio de agentes reductores.
DE69922958T3 (de) * 1998-06-24 2008-06-26 Innogenetics N.V. Hcv hüllproteine partikel : verwendung für therapeutische impfung

Also Published As

Publication number Publication date
AU4615299A (en) 2000-01-10
TR200003843T2 (tr) 2001-06-21
CA2330526A1 (en) 1999-12-29
HK1037639A1 (en) 2002-02-15
NZ528952A (en) 2004-09-24
US6635257B1 (en) 2003-10-21
DK1090033T4 (da) 2008-03-31
PL345018A1 (en) 2001-11-19
NZ508797A (en) 2004-02-27
CN1313864A (zh) 2001-09-19
ES2237115T3 (es) 2005-07-16
US20030202987A1 (en) 2003-10-30
ES2237115T5 (es) 2008-05-16
IL140217A0 (en) 2002-02-10
EP1555270A1 (en) 2005-07-20
DE69922958T2 (de) 2006-03-30
EP1090033A1 (en) 2001-04-11
BR9911397A (pt) 2002-01-15
DE69922958T3 (de) 2008-06-26
RU2247729C2 (ru) 2005-03-10
HUP0102478A3 (en) 2004-10-28
KR20010053181A (ko) 2001-06-25
PL201679B1 (pl) 2009-04-30
IL140217A (en) 2009-09-22
EP1090033B1 (en) 2004-12-29
DE69922958D1 (de) 2005-02-03
KR100559096B1 (ko) 2006-03-15
HU227275B1 (en) 2011-01-28
HUP0102478A2 (hu) 2001-10-28
JP2002518037A (ja) 2002-06-25
AU765940B2 (en) 2003-10-02
DK1090033T3 (da) 2005-04-25
US20060275323A1 (en) 2006-12-07
EP1090033B2 (en) 2007-12-19
ATE286067T1 (de) 2005-01-15
WO1999067285A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
PT1090033E (pt) Particulas de proteinas de envelope do hcv: utilizacao para vacinacao
BR9814487A (pt) "vacina"
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
MA24638A1 (fr) Vaccin
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
DK11789D0 (da) Rekombinante vaccinia-vira
AU2196592A (en) Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
EE200200709A (et) Liitvalku sisaldava kompositsiooni ning seda liitvalku ja liitpolüpeptiidi kodeeriva nukleiinhappe kasutamine
AU6160201A (en) Human polypeptides causing or leading to the killing of cells including lymphoidtumor cells
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
BRPI0113155B8 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
AU9215101A (en) Vaccines containing ribavirin and methods of use thereof
EP1613345A4 (en) COMPOSITIONS AND METHODS WITH THE RESPIRATORY SYNCYTIAL VIRUS SUB-GROUP B STAMM 9320
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
BR0112020A (pt) Partìculas tipo vìrus de bvdv
DK1165102T3 (da) Matrixproteinpræparater til podning i ikke-mineraliseret væv
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
DE60131975D1 (de) Anwendung des herpes simplex virus glykoproteins-d zur unterdrückung von immunantworten
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO2003022880A3 (en) Synthetic hcv envelope proteins and their use for vaccination
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung